Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats.

Date publication

juin 2016

Journal

British journal of pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr RODRIGUEZ-GUEANT Rosa-Maria

Tous les auteurs :
Youcef G, Olivier A, Nicot N, Muller A, Deng C, Labat C, Fay R, Rodriguez-Guéant RM, Leroy C, Jaisser F, Zannad F, Lacolley P, Vallar L, Pizard A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26990406

Résumé

Mineralocorticoid receptor (MR) activation contributes to heart failure (HF) progression. Its overactivity in obesity is thought to accelerate cardiac remodelling and HF development. Given that MR antagonists (MRA) are beneficial in chronic HF patients, we hypothesized that early MRA treatment may target obesity-related disorders and consequently delay the development of HF.

Mots clés

Animals, Diterpenes, Kaurane, administration & dosage, Male, Mineralocorticoid Receptor Antagonists, administration & dosage, Obesity, metabolism, Rats, Rats, Inbred SHR, Receptors, Mineralocorticoid, metabolism

Référence

Br J Pharmacol. 2016 06;173(11):1805-19